Merck and MD Anderson announce immuno-oncology research collaboration in solid tumors

Merck and The University of Texas MD Anderson Cancer Center announced a strategic clinical research collaboration to evaluate Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation therapy and/or novel anti-tumor medicines.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news